FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308407003> ?p ?o ?g. }

• W4308407003 abstract "<h3>Background</h3> Enrichment of memory B cells, plasma cells and tertiary lymphoid structure is a positive prognostic factor in patients with a variety of solid tumors.^1-3 Toll-like receptor 9 (TLR9) agonists generate both innate and adaptive immune responses. TLR9 activation in B cells has been shown to induce expression of co-stimulatory molecules, enhanced cross-presentation leading to T cell activation and proliferation, cytokine, chemokine and immunoglobulin secretion. Designed for systemic administration, TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC) comprised of a potent and differentiated TLR9 agonist (T-CpG) conjugated to an antibody against CD22, a receptor restricted to B cells, including tumor-infiltrating B cells. In preclinical models, TAC-001 has demonstrated single agent anti-tumor activity in checkpoint inhibitor resistant and refractory tumor models, accompanied by increased B cell infiltration, T cell effector functions and modulation of suppressive myeloid cells within the tumor microenvironment.⁴ INCLINE-101 is a Phase 1/2 study designed to evaluate the safety, efficacy, pharmacokinetics (PK) and biomarkers of TAC-001 in patients with select advanced or metastatic solid tumors. <h3>Methods</h3> TAC-001 is being evaluated in an open-label, non-randomized, dose-escalation (Phase 1) study in patients with select advanced or metastatic solid tumors, and dose-expansion (Phase 2) in patients with select tumor types (NCT05399654). Eligible patients in Phase 1 must have histologically or cytologically-documented advanced, metastatic, unresectable or recurrent breast cancer, cervical squamous cell carcinoma, cholangiocarcinoma, colorectal carcinoma, cutaneous melanoma, endometrial carcinoma, gastro-esophageal adenocarcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, Merkle cell carcinoma, non-small cell lung cancer, ovarian cancer, renal cell carcinoma, or urothelial carcinoma that have progressed on or are intolerant to standard therapy, including checkpoint inhibitor therapy if appropriate. Phase 1 study will explore ascending dose levels of TAC-001 monotherapy administrated intravenously every 2 weeks and utilize the Bayesian Optimal Interval (BOIN) design in order to identify the maximum tolerated dose (MTD) or maximum administered dose (MAD), and recommended Phase 2 dose (RP2D). Once RP2D is determined, the Phase 2 expansion in four specific tumor-type cohorts is planned. A 2-stage design will be utilized for Phase 2, and the Clopper-Pearson method to compute exact confidence limits for the response rates will be employed. The primary endpoints are safety and preliminary efficacy (overall response rate, duration of response, clinical benefit rate) per RECIST v1.1 and iRECIST. Additional endpoints include PK, immunogenicity, progression free survival, overall survival, and changes in relevant biomarkers. INCLINE-101 is enrolling in the USA and Australia. <h3>Trial Registration</h3> NCT05399654 <h3>References</h3> Griss J, Bauer W, Wagner C, <i>et al</i>. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. <i>Nat Commun</i>. 2019;<b>10</b>(1):4186. Helmink, B.A., Reddy, S.M., Gao, J. <i>et al</i>. B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> 2020;<b>577</b>:549–555. Kroeger DR, Milne K, Nelson BH. Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer. <i>Clin Cancer Res</i>. 2016;<b>22</b>(12):3005–3015. Kuo TC, Harrabi O, Chen A, Sangalang ER, Doyle L, Fontaine D, Li M, Han B, Pons J, Sim J, Wan HI. TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes anti-tumor immunity and favorable safety profile following systemic administration in preclinical models. <i>Cancer Res</i> 2021;<b>81</b>(13_Supplement):1721. <h3>Ethics Approval</h3> The study has received ethics approval from the WCG IRB (tracking number 20222058, study numbers 1334808 and 1334807) and Bellberry Human Research Ethics Committee (application number 2022-04-408)." @default.
• W4308407003 created "2022-11-11" @default.
• W4308407003 creator A5013744957 @default.
• W4308407003 creator A5020605893 @default.
• W4308407003 creator A5029745538 @default.
• W4308407003 creator A5030834372 @default.
• W4308407003 creator A5032366346 @default.
• W4308407003 creator A5033020983 @default.
• W4308407003 creator A5033884558 @default.
• W4308407003 creator A5061843649 @default.
• W4308407003 creator A5071560112 @default.
• W4308407003 creator A5072305232 @default.
• W4308407003 date "2022-11-01" @default.
• W4308407003 modified "2023-10-16" @default.
• W4308407003 title "756 INCLINE-101, a phase 1/2, open label, dose escalation and expansion study of TAC-001 (a TLR9 agonist conjugated to a CD22 antibody) in patients with select advanced or metastatic solid tumors" @default.
• W4308407003 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0756" @default.
• W4308407003 hasPublicationYear "2022" @default.
• W4308407003 type Work @default.
• W4308407003 citedByCount "0" @default.
• W4308407003 crossrefType "proceedings-article" @default.
• W4308407003 hasAuthorship W4308407003A5013744957 @default.
• W4308407003 hasAuthorship W4308407003A5020605893 @default.
• W4308407003 hasAuthorship W4308407003A5029745538 @default.
• W4308407003 hasAuthorship W4308407003A5030834372 @default.
• W4308407003 hasAuthorship W4308407003A5032366346 @default.
• W4308407003 hasAuthorship W4308407003A5033020983 @default.
• W4308407003 hasAuthorship W4308407003A5033884558 @default.
• W4308407003 hasAuthorship W4308407003A5061843649 @default.
• W4308407003 hasAuthorship W4308407003A5071560112 @default.
• W4308407003 hasAuthorship W4308407003A5072305232 @default.
• W4308407003 hasBestOaLocation W43084070031 @default.
• W4308407003 hasConcept C104317684 @default.
• W4308407003 hasConcept C121608353 @default.
• W4308407003 hasConcept C126322002 @default.
• W4308407003 hasConcept C143998085 @default.
• W4308407003 hasConcept C150194340 @default.
• W4308407003 hasConcept C170493617 @default.
• W4308407003 hasConcept C185592680 @default.
• W4308407003 hasConcept C190727270 @default.
• W4308407003 hasConcept C2776107976 @default.
• W4308407003 hasConcept C2777701055 @default.
• W4308407003 hasConcept C2778938600 @default.
• W4308407003 hasConcept C2779138994 @default.
• W4308407003 hasConcept C502942594 @default.
• W4308407003 hasConcept C55493867 @default.
• W4308407003 hasConcept C71924100 @default.
• W4308407003 hasConceptScore W4308407003C104317684 @default.
• W4308407003 hasConceptScore W4308407003C121608353 @default.
• W4308407003 hasConceptScore W4308407003C126322002 @default.
• W4308407003 hasConceptScore W4308407003C143998085 @default.
• W4308407003 hasConceptScore W4308407003C150194340 @default.
• W4308407003 hasConceptScore W4308407003C170493617 @default.
• W4308407003 hasConceptScore W4308407003C185592680 @default.
• W4308407003 hasConceptScore W4308407003C190727270 @default.
• W4308407003 hasConceptScore W4308407003C2776107976 @default.
• W4308407003 hasConceptScore W4308407003C2777701055 @default.
• W4308407003 hasConceptScore W4308407003C2778938600 @default.
• W4308407003 hasConceptScore W4308407003C2779138994 @default.
• W4308407003 hasConceptScore W4308407003C502942594 @default.
• W4308407003 hasConceptScore W4308407003C55493867 @default.
• W4308407003 hasConceptScore W4308407003C71924100 @default.
• W4308407003 hasLocation W43084070031 @default.
• W4308407003 hasOpenAccess W4308407003 @default.
• W4308407003 hasPrimaryLocation W43084070031 @default.
• W4308407003 hasRelatedWork W2178868239 @default.
• W4308407003 hasRelatedWork W2553442423 @default.
• W4308407003 hasRelatedWork W2771066073 @default.
• W4308407003 hasRelatedWork W3123929348 @default.
• W4308407003 hasRelatedWork W3195008613 @default.
• W4308407003 hasRelatedWork W3210687804 @default.
• W4308407003 hasRelatedWork W4303613753 @default.
• W4308407003 hasRelatedWork W4308769187 @default.
• W4308407003 hasRelatedWork W4312075079 @default.
• W4308407003 hasRelatedWork W4376226404 @default.
• W4308407003 isParatext "false" @default.
• W4308407003 isRetracted "false" @default.
• W4308407003 workType "article" @default.